Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
| Revenue (Most Recent Fiscal Year) | $3.92M |
| Net Income (Most Recent Fiscal Year) | $-126.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 315.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2870.32% |
| Net Margin (Trailing 12 Months) | -2868.66% |
| Return on Equity (Trailing 12 Months) | -842.83% |
| Return on Assets (Trailing 12 Months) | -78.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.42 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 297.97M |
| Free Float | 157.63M |
| Market Capitalization | $1.37B |
| Average Volume (Last 20 Days) | 16.49M |
| Beta (Past 60 Months) | 1.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 47.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 33.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |